Alzheimer's disease drug development and the problem of the blood-brain barrier

Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the pres...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2009-09, Vol.5 (5), p.427-432
1. Verfasser:	Pardridge, William M
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Biopharmaceuticals Blood-brain barrier Blood-Brain Barrier - drug effects Blood-Brain Barrier - physiology Brain drug targeting Central Nervous System Agents - pharmacokinetics Drug Delivery Systems - methods Drug Design Endogenous transporters Humans Neurology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and ∼100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein >99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and
ISSN:	1552-5260 1552-5279
DOI:	10.1016/j.jalz.2009.06.003